D-Glutamate

D-Glutamate

SCHEMBL3499202

Br.N[C@@H](CCC(=O)O)C(=O)[O-].N[C@@H](CCC(=O)O)C(=O)[O-].[Mg+2]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A known ✓ Q12879 1/20 0.60
SLC6A2 known ✓ P23975 1/20 0.43
SLC6A4 known ✓ P31645 1/20 0.43
SLC6A3 known ✓ Q01959 1/20 0.43
CYP1A2 P05177 2/20 0.60
GRM8 O00222 1/20 0.60
GRM6 O15303 1/20 0.60
GRIN2D O15399 1/20 0.60
GRIN3B O60391 1/20 0.60
GSR P00390 1/20 0.60
GRIK1 P39086 1/20 0.60
GRM5 P41594 1/20 0.60
GRIA1 P42261 1/20 0.60
GRIA2 P42262 1/20 0.60
GRIA3 P42263 1/20 0.60
SLC1A3 P43003 1/20 0.60
SLC1A2 P43004 1/20 0.60
SLC1A1 P43005 1/20 0.60
GRIA4 P48058 1/20 0.60
GRIN1 Q05586 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL218574 0.98 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL9646845 0.95 CYP1A2 (0.60) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL4025166 0.95 CYP1A2 (0.60) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL11697693 0.95 CYP1A2 (0.60) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL9241674 0.95 GRM8 (0.60) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL10824535 0.95 CYP1A2 (0.60) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL8987898 0.95 CYP1A2 (0.60) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL718336 0.93 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL1532402 0.93 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B
D-Glutamate SCHEMBL16336 0.93 CYP1A2 (0.62) CYP1A2GRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0108937-A2 Process for the production of amino-dicarboxylic acid-bivalent metal-halogen complexes and novel such complexes Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) 1984-05-23 EP claimed
US-12472203-B2 Composition and method for treating hearing loss Soundbites Public Benefit Corporation (US) 2025-11-18 US disclosed
US-20250268933-A1 COMPOSITION AND METHOD FOR TREATING HEARING LOSS Soundbites Public Benefit Corporation 2025-08-28 US disclosed
US-12329775-B2 Composition and method for treating hearing loss Soundbites Public Benefit Corporation (US) 2025-06-17 US disclosed
WO-2025038498-A2 COMPOSITION AND METHOD FOR TREATING HEARING LOSS Soundbites Public Benefit Corporation (US) 2025-02-20 WO disclosed
US-20250057875-A1 COMPOSITION AND METHOD FOR TREATING HEARING LOSS Soundbites Public Benefit Corporation 2025-02-20 US disclosed
US-20160369237-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECH INC (US) 2016-12-22 US disclosed
US-20100184033-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY Lineage Cell Therapeutics, Inc. 2010-07-22 US disclosed
US-20080226601-A1 Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods UNIVERSITY OF ROCHESTER (US) 2008-09-18 US disclosed
EP-1903873-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS THE UNIVERSITY OF ROCHESTER (US) 2008-04-02 EP disclosed
US-20080070303-A1 Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement ADVANCED CELL TECHNOLOGY 2008-03-20 US disclosed
WO-2007062198-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECHNOLOGY, INC. (US) 2007-05-31 WO disclosed
WO-2006135602-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS UNIVERSITY OF ROCHESTER (US) 2006-12-21 WO disclosed
EP-0108937-B1 PROCESS FOR THE PRODUCTION OF AMINO-DICARBOXYLIC ACID-BIVALENT METAL-HALOGEN COMPLEXES AND NOVEL SUCH COMPLEXES Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) 1989-01-25 EP disclosed
US-4546195-A Process for the production of amino-dicarboxylic acid-bivalent metal-halogen complexes and such complexes VERLA-PHARM, ARZNEIMITTELFABRIK, APOTHEKER H.J.V. EHRLICH GMBH & CO. KG (DE) 1985-10-08 US disclosed
EP-0108937-A2 Process for the production of amino-dicarboxylic acid-bivalent metal-halogen complexes and novel such complexes Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG (DE) 1984-05-23 EP disclosed
US-4041154-A Magnesium-containing pharmaceutical compositions VERLA-PHARM ARZNEIMITTEL-FABRIK APOTHEKER H. J. V. EHRLICH (DT) 1977-08-09 US disclosed